Provectus Biopharmaceuticals Announces Fourth Quarter 2024 Conference Call
Provectus Biopharmaceuticals (OTCQB: PVCT) has announced a conference call scheduled for Thursday, November 14, 2024 at 2 p.m. EST. The purpose of the call is to provide Company updates. Provectus has stated that the conference call details will be shared closer to the event date. This announcement indicates that the company is planning to communicate important information to its stakeholders, which could potentially include updates on financial performance, research and development progress, or other significant business developments.
Provectus Biopharmaceuticals (OTCQB: PVCT) ha annunciato una conference call programmata per giovedì 14 novembre 2024 alle 14:00 EST. Lo scopo della chiamata è fornire aggiornamenti sull'azienda. Provectus ha dichiarato che i dettagli della conference call saranno condivisi più vicino alla data dell'evento. Questo annuncio indica che l'azienda prevede di comunicare informazioni importanti ai suoi stakeholder, che potrebbero includere aggiornamenti sulle performance finanziarie, sul progresso della ricerca e sviluppo, o su altri sviluppi aziendali significativi.
Provectus Biopharmaceuticals (OTCQB: PVCT) ha Anunciado una conferencia telefónica programada para jueves 14 de noviembre de 2024 a las 2 p.m. EST. El propósito de la llamada es proporcionar actualizaciones de la empresa. Provectus ha declarado que los detalles de la conferencia telefónica se compartirán más cerca de la fecha del evento. Este anuncio indica que la empresa planea comunicar información importante a sus partes interesadas, que podría incluir actualizaciones sobre el rendimiento financiero, el progreso de la investigación y el desarrollo, o otros desarrollos empresariales significativos.
Provectus Biopharmaceuticals (OTCQB: PVCT)가 2024년 11월 14일 목요일 오후 2시 EST에 예정된 컨퍼런스 콜을 발표했습니다. 콜의 목적은 회사의 업데이트를 제공하는 것입니다. Provectus는 컨퍼런스 콜의 세부사항이 이벤트 날짜에 가까워지면 공유될 것이라고 밝혔습니다. 이 발표는 회사가 이해관계자에게 중요한 정보를 전달할 계획임을 나타내며, 이는 재무 성과, 연구 및 개발 진행 상황, 또는 기타 중요한 비즈니스 개발에 대한 업데이트를 포함할 수 있습니다.
Provectus Biopharmaceuticals (OTCQB: PVCT) a annoncé une conférence téléphonique prévue pour jeudi 14 novembre 2024 à 14h EST. L'objectif de cet appel est de fournir des mises à jour sur l'entreprise. Provectus a déclaré que les détails de la conférence téléphonique seraient partagés plus près de la date de l'événement. Cette annonce indique que l'entreprise prévoit de communiquer des informations importantes à ses parties prenantes, ce qui pourrait inclure des mises à jour sur les performances financières, l'avancement de la recherche et du développement ou d'autres développements commerciaux significatifs.
Provectus Biopharmaceuticals (OTCQB: PVCT) hat eine Konferenzschaltung angekündigt, die für Donnerstag, den 14. November 2024 um 14:00 Uhr EST geplant ist. Zweck des Anrufs ist es, Unternehmensupdates bereitzustellen. Provectus hat erklärt, dass die Einzelheiten der Konferenzschaltung näher an dem Datum des Ereignisses mitgeteilt werden. Diese Ankündigung zeigt, dass das Unternehmen plant, wichtige Informationen an seine Stakeholder zu kommunizieren, zu denen möglicherweise Aktualisierungen zur finanziellen Leistung, zum Fortschritt von Forschung und Entwicklung oder zu anderen bedeutenden geschäftlichen Entwicklungen gehören könnten.
- None.
- None.
KNOXVILLE, Tenn., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) announced today that it will host a conference call on Thursday, November 14, 2024 starting at 2 p.m. EST to provide Company updates.
Conference call details will be provided closer to the date of the event.
About Provectus
Provectus Biopharmaceuticals is a clinical-stage biotechnology company developing immunotherapy medicines for different diseases that are based on a class of bioactive synthetic small molecules called halogenated xanthenes. The Company’s lead molecule is named Rose Bengal Sodium. Provectus’s small molecule drug platform includes:
- Clinical development programs in oncology, dermatology, and ophthalmology
- In vivo proof-of-concept programs in oncology, hematology, full-thickness cutaneous wound healing, and canine cancers, and
- In vitro discovery programs in infectious diseases, tissue regeneration and repair, and several proprietary targets.
Information about the Company’s clinical trials can be found at the National Institutes of Health (NIH) registry, ClinicalTrials.gov. For additional information about Provectus, please visit the Company’s website at www.provectusbio.com.
Forward Looking Statements
The information in this press release may include “forward-looking statements,” within the meaning of the Private Securities Litigation Reform Act of 1995, relating to the business of Provectus and its affiliates, which are based on currently available information and current assumptions, expectations, and projections about future events and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as “aim,” “likely,” “outlook,” “seek,” “anticipate,” “budget,” “plan,” “continue,” “estimate,” “expect,” “forecast,” “may,” “will,” “would,” “project,” “projection,” “predict,” “potential,” “targeting,” “intend,” “can,” “could,” “might,” “should,” “believe,” and similar words suggesting future outcomes or statements regarding an outlook.
The safety and efficacy of the agents and/or uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated or that such agents as products will achieve any particular revenue levels.
Due to the risks, uncertainties, and assumptions inherent in forward-looking statements, readers should not place undue reliance on these forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof or as of the date specifically specified herein, and Provectus undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except in accordance with applicable securities laws. The forward-looking statements are expressly qualified by this cautionary statement.
Risks, uncertainties, and assumptions include those discussed in the Company’s filings with the U.S. Securities and Exchange Commission (SEC), including those described in Item 1A of Provectus’s:
- Annual Report on Form 10-K for the period ended December 31, 2023, and
- Quarterly Report on Form 10-Q for the period ended June 30, 2024.
Contacts:
Provectus Biopharmaceuticals, Inc.
Heather Raines, CPA
Chief Financial Officer
hraines@pvct.com
(866) 594-5999
Investor Relations & Media
IR Labs Inc. (irlabs)
Alyssa Barry
alyssa@irlabs.ca
(833) 947-5227
FAQ
When is Provectus Biopharmaceuticals (PVCT) holding its Q4 2024 conference call?
What is the purpose of Provectus Biopharmaceuticals' (PVCT) upcoming conference call?
Has Provectus Biopharmaceuticals (PVCT) released the details for their Q4 2024 conference call?
What stock exchange is Provectus Biopharmaceuticals (PVCT) listed on?
